What specific complement components and functional targets should diagnostic developers include in IVD kits designed to evaluate complement system dysfunctions?

Diagnostic developers who only measure C3 and C4 are missing critical dysfunctions.
A truly comprehensive IVD kit for complement system evaluation must pair functional pathway screening with quantitative component detection. At a minimum, this means including a CH50 assay for classical pathway activity, an AH50 assay for alternative pathway integrity, and specific immunoassay reagents for C3, C4, C1q, and C5—backed by high‑purity protein calibrators and complement‑inactivating sample diluents to ensure robust analytical performance.

The real power of a complement diagnostics panel lies in answering two questions simultaneously: “Is any pathway broken?” and “Exactly where is the break?” Combining broad functional screens with targeted protein quantitation lets clinicians pinpoint the defect—from early classical component deficiencies to terminal pathway gaps that leave patients vulnerable to encapsulated bacteria—while also monitoring the impact of modern complement‑targeted therapies.

Why a Two‑Pronged Approach is Essential

A single test cannot capture the full picture of complement dysfunction.
Functional assays reveal whether the system can still generate its key effector molecules, while quantitative immunoassays identify which specific protein is missing or consumed.

The limitation of measuring only C3 and C4

Routine panels often stop at C3 and C4 because they are useful markers of immune‑complex consumption in diseases like systemic lupus erythematosus.
However, a normal C3/C4 result cannot rule out a deficiency in C1q, C2, C5, or any other component.
Many primary immunodeficiencies and drug‑induced states present with normal C3/C4 but a non‑functional terminal pathway—a blind spot that leaves patients undiagnosed and at risk.

How functional screens and quantitative panels complement each other

A depressed CH50 or AH50 result tells you that somewhere along the cascade, the complement system is failing.
Following up with quantitation of individual proteins then pinpoints whether the cause is a missing component, a consumed component, or an inhibitory effect.
This layered strategy is exactly what the primary reference describes: combine total complement activity screening with specific immunoassay reagents for C3, C4, C1q, and terminal components like C5 to get a precise, actionable profile.

The Core Functional Targets Your Kit Must Include

Functional assays form the front line of any serious complement evaluation.
Without them, even a complete set of quantitative measurements can fail to reveal a functional protein defect or a regulatory imbalance.

CH50 – classical pathway and terminal cascade screening

The CH50 hemolytic assay measures the ability of patient serum to lyse antibody‑sensitized sheep erythrocytes.
It requires a fully operational classical pathway (C1, C4, C2) and an intact terminal pathway (C3, C5–C9).
A low or absent CH50 signals a deficiency anywhere from C1q through C9, but it will not detect an isolated alternative pathway defect.
Developers should include standardized sensitized erythrocytes, a validated reference serum, and clear lot‑to‑lot calibration controls to make this assay reliable across clinical laboratories.

AH50 – the missing piece for alternative pathway defects

While the primary reference emphasizes CH50, leaving out the alternative pathway screen creates a dangerous gap.
AH50 uses rabbit erythrocytes or other alternative pathway activators to measure function when classical and lectin pathways are blocked.
Deficiencies in factor D, properdin, or a C3 defect that spares the classical route can present with a normal CH50 but a flatlined AH50.
Including both CH50 and AH50 ensures your kit can detect the full spectrum of inherited and acquired complement deficiencies.

The Quantitative Components That Pinpoint the Defect

Once a functional screen is abnormal, the next job of the IVD kit is to identify the missing or depleted protein.
Your quantitative panel must cover the intersection points of clinical relevance and assay practicality.

C3 – the central hub you cannot omit

C3 sits at the convergence of all three activation pathways.
A C3 deficiency leads to severe, recurrent infections with encapsulated bacteria (especially Streptococcus pneumoniae) and immune‑complex disorders such as glomerulopathies.
Even without complete deficiency, low C3 often signals active consumption in autoimmune diseases.
Your kit should provide a high‑purity C3 calibrator, a matched antibody pair, and a protocol that is compatible with both turbidimetric and ELISA formats to maximize laboratory compatibility.

C4 – a window into classical pathway load

C4 measurement is a routine staple for monitoring lupus activity, but it is also the starting point for detecting partial classical pathway deficiencies.
Complete C4 deficiency strongly predisposes individuals to lupus‑like syndromes.
Because C4 can drop from consumption in immune‑complex disease, serial quantitation helps distinguish a genetic deficiency from an inflammatory flare‑up.

C1q – the often‑overlooked lupus marker

C1q deficiency carries the highest risk for systemic lupus erythematosus among all complement defects.
Adding C1q quantitation to the panel directly addresses the clinical phenotype highlighted by the references: classical pathway component deficiencies lead to autoimmune syndromes and recurrent infections.
Supplying a validated C1q standard is especially important because C1q is a large, multimeric protein that requires careful purification and stabilization to serve as a reliable calibrator.

C5 and terminal pathway integrity

C5 measurement is no longer optional.
The widespread use of terminal complement C5 inhibitors (such as eculizumab) creates a patient population that is pharmacologically C5‑deficient and at heightened risk for systemic Neisseria infections.
Quantifying C5 lets clinicians confirm drug efficacy, monitor dosing, and assess susceptibility.
Your kit should include a C5‑specific antibody pair and, ideally, the ability to report whether the C5 molecule is functionally intact or bound by inhibitor—potentially through a separate competitive or activity‑based add‑on.

Understanding the Trade‑offs and Common Pitfalls

Designing a robust complement assay panel is not just about choosing the right analytes.
You also have to solve the pre‑analytical and manufacturing challenges that can erode assay performance.

Sample stability – the hidden variable

Complement proteins are notoriously labile.
In‑vitro activation can occur rapidly if serum is not separated and frozen promptly, leading to artificially low C3 and C4 and a falsely depressed CH50.
Your kit must include clear guidance on sample collection (preferably in EDTA at 4 °C) and offer complement‑inactivating sample diluents that block further activation during the assay itself.

Interference from active complement in immunoassays

Serum complement can create non‑specific background noise, especially in sandwich ELISAs.
Including a dedicated sample diluent that neutralizes complement activity eliminates this risk and improves signal‑to‑noise ratios.
This requirement is often underestimated but is critical for robust lot‑to‑lot consistency.

Cost versus clinical yield

A panel covering CH50, AH50, C3, C4, C1q, and C5 is comprehensive but not trivial in terms of reagent cost and instrument time.
Developers can consider modular designs: a core functional duo plus C3/C4 for high‑volume autoimmune testing, and an extended panel that adds C1q and C5 for specialized immunology centers.
This tiered approach balances market adoption with clinical depth.

Making the Right Choice for Your IVD Development Goal

The exact panel composition depends on the clinical scenario you want to address.
Use the following recommendations to tailor your kit to the intended diagnostic niche.

• If your primary focus is broad primary immunodeficiency screening: Include CH50, AH50, and quantitative assays for C3, C4, C1q, and C5 to capture both early classical defects and terminal pathway weaknesses.
• If your primary focus is monitoring patients on C5 inhibitor therapy: Prioritize a reliable C5 quantitation assay alongside a CH50 functional test to confirm terminal pathway blockade, and add C3/C4 to rule out concurrent consumption.
• If your primary focus is routine autoimmune disease assessment: A streamlined panel of CH50, C3, and C4 delivers the highest clinical impact at the lowest cost, with the option to reflex to C1q when lupus is suspected.
• If your primary focus is high‑throughput immunology laboratories: Supply all core analytes as ready‑to‑use, standardized reagent sets with matched calibrators and complement‑inhibiting diluents to minimize inter‑laboratory variability.

Combining functional and quantitative complement testing transforms a generic IVD kit into a definitive diagnostic tool—one that can catch the rare deficiency others miss and guide modern, targeted therapies with confidence.

Summary Table:

Ready to accelerate your complement assay development? CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to premium IVD raw materials, technical services, and expert consulting—covering every stage from concept to clinic. Whether you need high-purity protein calibrators, matched antibody pairs, or specialized complement-inactivating diluents, we are here to support your success. Contact us today to optimize your diagnostic kits!